Iterative Scopes Raises $30 Million Series A Financing To Advance Ai-Driven Precision Medicine For Gastroenterology

Aug 03, 2021•about 4 years ago

Amount Raised

$30 Million

Round Type

series a

Cambridge

Description

Iterative Scopes, a pioneering company aiming to bring cutting-edge precision medicine to gastroenterology, today disclosed that it has closed a $30 million Series A financing. The round was led by new investor Obvious Ventures, with participation from Eli Lilly, Johnson & Johnson Innovation – JJDC Inc., the venture capital firms Breyer Capital and Seae Ventures, as well as a number of leaders in healthcare, including Lee Shapiro, Zach Weinberg and Nat Turner. The funds will be used to further develop the company’s core algorithmic innovations and to advance its growing life sciences businesses.

Company Information

Company

Iterative Scopes

Location

Cambridge, Maryland, United States

About

Iterative Scopes is fast becoming the leader in computational gastroenterology through its pioneering application of powerful, proprietary artificial intelligence tools to the practice of gastroenterology and drug development. It is taking a multi-tiered approach to tackling the challenges of endoscopic-driven disease management. The initial products and services offered by Iterative Scopes aim to identify and standardize relevant insights from endoscopic videos used for detection and monitoring of colorectal cancers and inflammatory bowel disease (IBD). Longer term, the company is building predictive models that can augment clinical trial endpoints and individualized therapeutic selection processes, with the potential to create novel endpoints that are better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the team is based in Cambridge, Massachusetts. For more information, visit www.iterativescopes.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech